Argenx
ARGX
#417
Rank
C$77.70 B
Marketcap
C$1,248
Share price
-0.05%
Change (1 day)
44.35%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Earnings for Argenx (ARGX)

Earnings in 2025 (TTM): C$1.34 Billion

According to Argenx 's latest financial reports the company's current earnings are C$3.60 Billion. In 2024 the company made an earning of C$0.11 Billion, an increase over its 2023 earnings that were of -C$0.43 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Argenx from 2013 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) C$1.34 B1038.31%
2024 C$0.11 B-127.97%
2023 -C$0.43 Billion-58.25%
2022 -C$1.02 Billion
2019 -C$0.28 Billion124.86%
2018 -C$0.13 Billion131.81%
2017 -C$52.85 Million54.9%
2016 -C$34.12 Million33.71%
2015 -C$25.52 Million12.93%
2014 -C$22.6 Million46.39%
2013 -C$15.44 Million